
From risk to resilience
Peng Fu, CEO, and Estrid Jakobsen, Communications Lead… Read More

Peng Fu, CEO, and Estrid Jakobsen, Communications Lead… Read More

The DDW Turning Science into Business Symposium will take place at the Francis Crick Institute in London on Tuesday 4 November. Daniil Bash DDW is delighted to welcome Dr Daniil Bash, Lead Scientist at the Innovation Centre in Digital Molecular Technologies (iDMT), University of Cambridge,… Read More

Neurological biomarker research is advancing rapidly, but key challenges remain. Download this new Whitepaper from Olink entitled ‘Navigating neurological biomarker research: Progress, learnings and future directions’. The Whitepaper captures: Expert perspectives from academia and biopharma Highlighting successes, setbacks, and strategies for translational advancements in Alzheimer’s, Parkinson’s, and MS. A… Read More

Neurological biomarker research is advancing rapidly, but key challenges remain. This Whitepaper captures: Expert perspectives from academia and biopharma Highlighting successes, setbacks, and strategies for translational advancements in Alzheimer’s, Parkinson’s, and MS. A must-read for researchers navigating the future of precision neurology. Read More

Join DDW and Curia on 14 October for a webinar on how X-ray crystallography can accelerate the drug design process. The first challenge in drug discovery is selecting a biological target and validating it as a ‘druggable’ binding site. The key to this is identifying several… Read More

David Nirschl, Head, Life Sciences Consulting, Thermo Fisher Scientific and Santosh Vijay, Senior Director, Program Management, Thermo Fisher Scientific explore how to harness innovation for speed,… Read More

Biomarker discovery and validation are critical for advancing personalised medicine and improving therapeutic outcomes. However, the complexity of high-throughput assays and image-based analyses presents significant challenges in extracting meaningful insights efficiently. Taking place on 23 October at 4pm BST, this webinar, hosted by DDW and supported by Danaher Life… Read More

John Lepore, MD, CEO of ProFound Therapeutics, explore how multiomics, combined with artificial intelligence and real-world data is advancing drug discovery. The drug discovery landscape is undergoing a transformative shift, driven by the growing demand for precision medicine and tremendous technological advances that inform systems biology. Traditional R&D approaches… Read More

Dr Kenneth Barr, Head of Strategic Collaborations at Syngene, explores how early-phase drug development is moving towards integrated translational strategies. Drug development continues to grow in complexity, risk, and cost. With timelines stretching over a decade and the average spend per new drug exceeding $2.6 billion, many… Read More

The recent state visit to the UK by US President Trump was accompanied by the unveiling of a ‘US-UK tech partnership’ on 16 September. DDW speaks to experts at MHA’s life science team, who advise biotechnology and pharma firms in both the UK and… Read More

The use of artificial intelligence (AI) continues to rise, according to the results of the Pistoia Alliance’s annual Lab of the Future survey. The results show that 77% of respondents expect to use AI in the next two years. It also remains the number one investment area… Read More

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the week to keep DDW subscribers up-to-date with the latest industry news. This week’s news is led by the agreement by Genmab to acquire Merus, an announcement… Read More

The DDW Turning Science into Business Symposium will take place at the Francis Crick Institute in London on Tuesday 4 November. Lawrence Welch DDW is delighted to welcome Lawrence Welch, Inside Sales Specialist, Nuclera, to the expert speaker line-up. Lawrence Welch supports the… Read More

In this case study, we test the predictive abilities of Free Energy Perturbation (FEP) to arrive at accurate binding free energies for ‘new’ ligand suggestions within the TYK2 system. Computational methods used include: Molecular Dynamics (MD) Water analysis solving the Ornstein-Zernike equation (3D-RISM) Alignment of ligands for FEP (Conformation… Read More

Antibody-drug conjugates (ADCs) offer a targeted approach to cancer treatment, combining the specificity of antibodies with the potency of cytotoxic drugs, and have shown promise in improving patient outcomes. They have enjoyed considerable commercial success, particularly in treating cancer, and as a result various different types… Read More

By Reece Armstrong Artificial intelligence is no longer just a vision for drug discovery — it is becoming a practical tool in the laboratory and a driver of new ways of working. At the recent “Data & AI to Accelerate Drug Discovery” summit, co-hosted by CAS, a division… Read More